Dr Dylan Kiltschewskij is an early career statistical geneticist with over a decade of experience in genetic research. His work integrates bioinformatics, statistical modelling, and genomics to uncover novel therapeutic avenues and advance precision medicine for psychiatric conditions, including schizophrenia, major depressive disorder, and bipolar disorder.

Dr Kiltschewskij’s research program is built around three core pillars at the interface of discovery and translational research:

1.Genomic discovery for therapeutic innovation – Identifying novel drug targets and repurposing opportunities in psychiatric illness, with a particular focus on cardiometabolic factors such as circulating metabolites.
2.Epigenetic mechanisms in psychiatry – Determining the epigenetic basis of psychiatric conditions to better understand how the epigenome contributes to variability in onset, progression, severity, and treatment response.
3.Enabling precision medicine – Harnessing individual genomic risk profiles to inform personalised interventions and improve clinical outcomes.

Across these themes, Dr Kiltschewskij has led studies published in high-impact journals in the field of psychiatric genetics, including Molecular Psychiatry, Biological Psychiatry, and Translational Psychiatry. This body of work builds significantly on his PhD research (2016–2020), which explored how non-coding microRNAs control mRNA dynamics in the neuronal context, shedding light on the implications of microRNA dysregulation in psychiatric disorders.

Through this work, Dr Kiltschewskij has cultivated a broad, interdisciplinary skillset spanning biostatistics, bioinformatics, big data analytics, and systems biology. His expertise has fostered multidisciplinary collaborations ranging from paediatric brain cancer to chemotherapeutic cardiotoxicity and nutritional biology.